RIGL vs. FN

Last updated Apr 1, 2026

Compare and contrast key facts about Rigel Pharmaceuticals, Inc. (RIGL) and Fabrinet (FN).

Performance

RIGL vs. FN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Rigel Pharmaceuticals, Inc. (RIGL) and Fabrinet (FN). The values are adjusted to include any dividend payments, if applicable.

RIGL vs. FN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
RIGL Rigel Pharmaceuticals, Inc.	-36.87%	154.64%	16.00%	-3.33%	-43.40%	-24.29%	63.55%	-6.96%	-40.72%	63.03%
FN Fabrinet	14.55%	107.06%	15.53%	48.44%	8.23%	52.69%	19.66%	26.37%	78.78%	-28.78%

Fundamentals

Market Cap RIGL : $509.43M FN : $18.87B
EPS RIGL : $19.61 FN : $10.36
PE Ratio RIGL : 1.38 FN : 50.35
PEG Ratio RIGL : 0.00 FN : 2.16
PS Ratio RIGL : 1.72 FN : 4.84
PB Ratio RIGL : 1.30 FN : 8.64
Total Revenue (TTM) RIGL : $294.28M FN : $3.89B
Gross Profit (TTM) RIGL : $274.66M FN : $467.60M
EBITDA (TTM) RIGL : $129.72M FN : $458.04M

Returns By Period

In the year-to-date period, RIGL achieves a -36.87% return, which is significantly lower than FN's 14.55% return. Over the past 10 years, RIGL has underperformed FN with an annualized return of 1.99%, while FN has yielded a comparatively higher 32.12% annualized return.

RIGL

• 1D: 5.13%
• 1M: -22.16%
• YTD: -36.87%
• 6M: -4.55%
• 1Y: 50.31%
• 3Y*: 27.00%
• 5Y*: -4.65%
• 10Y*: 1.99%

FN

• 1D: 6.03%
• 1M: -4.42%
• YTD: 14.55%
• 6M: 43.03%
• 1Y: 164.05%
• 3Y*: 63.76%
• 5Y*: 41.68%
• 10Y*: 32.12%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

RIGL vs. FN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RIGL

RIGL Risk / Return Rank: 66
RIGL Sharpe Ratio Rank: 67
RIGL Sortino Ratio Rank: 70
RIGL Omega Ratio Rank: 66
RIGL Calmar Ratio Rank: 63
RIGL Martin Ratio Rank: 63

FN

FN Risk / Return Rank: 93
FN Sharpe Ratio Rank: 95
FN Sortino Ratio Rank: 89
FN Omega Ratio Rank: 89
FN Calmar Ratio Rank: 98
FN Martin Ratio Rank: 97

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RIGL vs. FN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Rigel Pharmaceuticals, Inc. (RIGL) and Fabrinet (FN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RIGL	FN	Difference
Sharpe ratio Return per unit of total volatility	0.73	2.53	-1.80
Sortino ratio Return per unit of downside risk	1.58	2.67	-1.09
Omega ratio Gain probability vs. loss probability	1.19	1.37	-0.18
Calmar ratio Return relative to maximum drawdown	1.02	8.07	-7.05
Martin ratio Return relative to average drawdown	2.34	20.16	-17.82
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RIGL vs. FN - Sharpe Ratio Comparison

The current RIGL Sharpe Ratio is 0.73, which is lower than the FN Sharpe Ratio of 2.53. The chart below compares the historical Sharpe Ratios of RIGL and FN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	RIGL	FN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.73	2.53	-1.80
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.05	0.81	-0.86
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.02	0.68	-0.66
Sharpe Ratio (All Time) Calculated using the full available price history	-0.13	0.57	-0.70

Correlation

The correlation between RIGL and FN is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

RIGL vs. FN - Dividend Comparison

Neither RIGL nor FN has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

RIGL vs. FN - Drawdown Comparison

The maximum RIGL drawdown since its inception was -99.37%, which is greater than FN's maximum drawdown of -70.46%. Use the drawdown chart below to compare losses from any high point for RIGL and FN.

Drawdown Indicators

	RIGL	FN	Difference
Max Drawdown Largest peak-to-trough decline	-99.37%	-70.46%	-28.91%
Max Drawdown (1Y) Largest decline over 1 year	-50.08%	-20.55%	-29.53%
Max Drawdown (5Y) Largest decline over 5 years	-85.24%	-38.70%	-46.54%
Max Drawdown (10Y) Largest decline over 10 years	-86.40%	-51.11%	-35.29%
Current Drawdown Current decline from peak	-97.47%	-15.34%	-82.13%
Average Drawdown Average peak-to-trough decline	-90.87%	-22.78%	-68.09%
Ulcer Index Depth and duration of drawdowns from previous peaks	21.89%	8.23%	+13.66%

Volatility

RIGL vs. FN - Volatility Comparison

The current volatility for Rigel Pharmaceuticals, Inc. (RIGL) is 15.12%, while Fabrinet (FN) has a volatility of 28.70%. This indicates that RIGL experiences smaller price fluctuations and is considered to be less risky than FN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RIGL	FN	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.12%	28.70%	-13.58%
Volatility (6M) Calculated over the trailing 6-month period	51.08%	50.83%	+0.25%
Volatility (1Y) Calculated over the trailing 1-year period	69.36%	65.21%	+4.15%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	85.91%	51.79%	+34.12%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	82.83%	47.40%	+35.43%

Financials